Santé log

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive ...

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present efficacy data ...
Santé log

Progyny Expands Access to Fertility and Women’s Health with Industry’s First Fully Insured Supplemental Plan

First-of-its-kind plan expands access to comprehensive, outcomes-based family building and women’s health care with predictable costs for small U.S. employers. NEW YORK, April 1 ...
Santé log

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks CHICAGO, April 16, 2026 ...
Santé log

Virbac: forte croissance de +7,7 % au premier trimestre 2026 à pcc, portée par la croissance à deux chiffres de nos plateformes prioritaires Supercharge⁴

« Notre excellent début d'année souligne la force compétitive de notre modèle, porté par une performance très équilibrée sur nos segments Animaux de compagnie et Animaux de production. Nos plateformes ...
Santé log

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system (“CNS ...
Santé log

Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio

Partnership with AMI Technologies Positions FemaSeed ® as a First-Line Infertility Treatment in Israel, Expanding Market Access to Innovative Fertility Solutions -- ATLANTA, A ...
Santé log

Evaxion concludes Annual General Meeting

COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual ...
Santé log

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, including two podium presentations, at the American ...
Santé log

Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms

First-quarter 2026 revenue reached €384m : +7.7% at constant exchange rate and scope (CERS) vs Q1 2025 +2.2% at actual rates impacted by significant currency headwinds; Balanced ...
Santé log

Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its first quarter 2026 results on Thursday, May 7, 2026, after market close, and host a ...
Santé log

NBPure Launches at Target, Marking Major Retail Expansion

PHOENIX, April 16, 2026 (GLOBE NEWSWIRE) -- NBPure, a trusted leader in gut-first wellness for more than 28 years, today announced its expansion into Target, a significant milestone in the brand’s ...
Santé log

Dr. Falk Pharma and Renexxion Announce Late-Breaker Oral Presentation of Global Phase 2b Gastroparesis Results at Digestive Disease Week (DDW) 2026

Naronapride is a potential best-in-class oral, locally acting pan-GI prokinetic designed to enhance coordinated motility across the digestive tract. Naronapride works through a differentiated dual ...